ICOMETASONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H29ClO5
Molecular Weight	408.916
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(Cl)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=NBMKJKDGKREAPL-CXSFZGCWSA-N

InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://adisinsight.springer.com/drugs/800003939 | https://www.ncbi.nlm.nih.gov/pubmed/9608879 | https://www.ncbi.nlm.nih.gov/pubmed/11936562

Icometasone (CL09) is a synthetic glucocorticoid corticosteroid. It is a metabolite of Mometasone Furoate. The binding on human serum albumin was shown to be non saturable, suggesting that other proteins were involved in CL09 binding. This binding was demonstrated to be reversible. CL09 was extensively metabolized since no unchanged CL09 was recovered in bile or urine and at least nine metabolites have been detected. It was studied in Europe as an anti-asthmatic agent but investigation is discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Arachidonic acid 2 Target ID: Arachidonic acid Sources: http://adisinsight.springer.com/drugs/800003939	Inhibitor 8297
Lipocortin synthesis 2 Target ID: Lipocortin synthesis Sources: http://adisinsight.springer.com/drugs/800003939	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 241 Sources: http://adisinsight.springer.com/drugs/800003939 https://www.ncbi.nlm.nih.gov/pubmed/9608879	Primary		Preclinical	Unknown Approved Use Unknown
Skin diseases 10 Sources: http://adisinsight.springer.com/drugs/800003939	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.	1998 Apr	9608879
Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology.	2002 Apr	11936562

Patents

Sample Use Guides

In Vivo Use Guide

Rats: intravenous (1 mg/kg), oral and intratracheal (2 mg/kg).

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

ICOMETASONE

Common Name

English

(11.BETA.,16.ALPHA.)-9-CHLORO-11,17,21-TRIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE

Systematic Name

English

ICOMETHASONE

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 9-CHLORO-11,17,21-TRIHYDROXY-16-METHYL-, (11.BETA.,16.ALPHA.)-

Systematic Name

English

MOMETASONE FUROATE IMPURITY K [EP IMPURITY]

Common Name

English

Code System Code Type Description

FDA UNII

2LP8SJ795G